geht hier was

Glaube immer noch das wir mit Aviptadil einen Blockbuster
in Händen halten an den big Pharma nicht vorbei kommt ! :-)

https://www.blick.ch/schweiz/...en-bei-neuer-variante-id17081631.html  

Sehen wir bis Ende Jahr noch die 1 Rappen?
Irgendwie geht es nicht mehr vorwärts mit Relief.  

Für die, die es sich leisten können, und dann, ja vielleicht,
wenn alle lukrativen Möglichkeiten aus der Trickkiste gekommen sind,
dann ist der Professor wieder vom alten Mann zum Genie mutiert.
 

 
Ad hoc announcement pursuant to Art. 53 LR
1

Relief Therapeutics Reports the Successful Conclusion of the Patent Examination
Procedure  for  the  Patent  Application  Entitled,  “Vasoactive Intestinal Peptide
(VIP) for the Use in the Treatment of Drug-induced Pneumonitis”

Geneva, Switzerland,  December 28,  2021 – RELIEF THERAPEUTICS Holding  SA (SIX: RLF, OTCQB: RLFTF,
RLFTY)  (“Relief”),  a  biopharmaceutical  company  seeking  to  provide  patients  therapeutic  relief  from
serious  diseases  with  high unmet  need,  reported  today that the  Swiss  Patent  Office  IPI  has  announced
that it expects to conclude the patent application procedure by January 24, 2022 and to issue the patent
entitled, “Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis,”
as applied for by Relief’s subsidiary, AdVita Lifescience GmbH, in 2020. The patent will be formally issued,
at the earliest, one month after the conclusion of the patent examination procedure.
“The pending grant of this Swiss patent for the inhaled version of RLF-100™ (aviptadil) represents another
important milestone for the Company and further solidifies our growing intellectual property portfolio,”
stated Raghuram (Ram) Selvaraju, Chairman of Relief. “The potential benefits of this inhaled formulation
of RLF-100™ are intriguing and a number of studies to assess its advantages remain ongoing, including a
clinical  program  in  Europe  as  well  as  the  National Institutes of Health (“NIH”)-sponsored  ACTIVE-
3b/TESICO study and the I-SPY trial sponsored by Quantum Leap.”
Immune checkpoint inhibitor therapy has become a new therapeutic option for several types of cancer,
but immune related negative adverse events can limit their use. Outside of clinical studies, pneumonitis
develops  in  as  many  as  10%  to  20%  of  patients  who  are  treated  with  immune  checkpoint  inhibitors,  a
complication that leads to discontinuation of treatment and to immunosuppressive therapy. Moreover,
these  patients  suffer  from  recurrent  pneumonitis  even  after  immune  checkpoint  inhibitor  treatment
discontinuation  and  receipt  of  glucocorticoid  treatment,  according  to  current  guidelines.  Respiratory
symptoms  are  demonstrated  on  computed  tomography  showing  widespread  consolidations  and  are
denoted on  Quality  of  Life  Questionnaires.  Patients  experience  severe  lymphocytosis  with  a  decreased
number  of  regulatory  T  cells.  As  a  result,  there  is  an  urgent  need  for  an  effective,  safe  treatment  of
checkpoint inhibitor–induced pneumonitis.
The unexpected finding that the synthetic form of Vasoactive Intestinal Peptide (aviptadil) administered
via inhalation was well tolerated and led to dampening of alveolar inflammation, radiological and clinical
improvement of pneumonitis resulting from a checkpoint inhibitor therapy for melanoma, was the basis
for this issued Patent.  

 
Ad hoc announcement pursuant to Art. 53 LR
2


Inhalation  is  the  preferred  route  of  aviptadil  administration  in  that  it,  (1)  acts  quickly,  minimizing
potentially undesired negative side effects (2) avoids the hepatic first-pass metabolism, and (3) acts locally
in the lungs. As the size variability among adult lungs is smaller than overall body size variability, the dosing
reliability is also improved via inhalation.
This  finding  appeared  in  a  Case  Report  Publication  in  the  highly  prestigious  New  England  Journal  of
Medicine (Frye et al., 2020).
ABOUT RELIEF
Relief  focuses  primarily  on  clinical-stage  programs  based  on molecules with  a  history  of  clinical  testing
and use in human patients or a strong scientific rationale. Relief’s drug candidate, RLF-100™ (aviptadil), a
synthetic  form  of  Vasoactive  Intestinal  Peptide  (VIP),  is  in  late-stage  clinical  testing  in  the  U.S.  for  the
treatment  of  respiratory  deficiency  due  to  COVID-19.  As  part  of  its  pipeline  diversification  strategy,  in
March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the
worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate
release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle
Disorders  and  Maple  Syrup  Urine  Disease.  In  addition,  Relief's  recently  completed  acquisitions  of  APR
Applied Pharma Research SA and AdVita Lifescience GmbH bring to Relief a diverse pipeline of marketed
and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in
the U.S. on OTCQB under the symbols RLFTF and RLFTY.  For more information, visit
www.relieftherapeutics.com.  Follow us on LinkedIn.


CONTACT:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Financial Officer and Treasurer  
contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES:  
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com


 
 

Danke HellBoy 99

Vasoaktive intestinale Peptide bei Checkpoint-Inhibitor-induzierter Pneumonitis

Die Therapie mit Immun-Checkpoint-Inhibitoren hat sich zu einer neuen therapeutischen Option für verschiedene Krebsarten entwickelt, aber immunbedingte unerwünschte Ereignisse können ihren Einsatz einschränken.1 Außerhalb klinischer Studien entwickelt sich bei 10 bis 20 % der Patienten, die mit Immun-Checkpoint-Inhibitoren behandelt werden, eine Pneumonitis, eine Komplikation, die zum Abbruch der Behandlung und zu einer immunsuppressiven Therapie führt.

Ein 68-jähriger Mann, der wegen eines fortgeschrittenen Melanoms mit Pembrolizumab behandelt wurde (ein Fallbericht findet sich im ergänzenden Anhang, der zusammen mit dem Volltext dieses Briefes auf NEJM.org verfügbar ist), hatte eine rezidivierende Pneumonitis, selbst nach Absetzen der Behandlung und Erhalt einer Glukokortikoid-Behandlung gemäß den aktuellen Leitlinien.1 Seine Atemwegs- und Allgemeinsymptome wurden mit dem King's Sarcoidosis Questionnaire quantifiziert, und es wurde festgestellt, dass seine Werte in den Bereichen allgemeiner Gesundheitszustand und Lunge abnahmen. Die Computertomographie zeigte ausgedehnte Konsolidierungen (Abbildung 1A), ein Befund, der mit einer rezidivierenden Immun-Checkpoint-Inhibitor-Pneumonitis vereinbar ist. Die Analyse der bronchoalveolären Lavageflüssigkeit (BAL) schloss eine Infektion aus, zeigte jedoch eine Lymphozytose mit verminderten regulatorischen T-Zellen, wie sie bei Immun-Checkpoint-Inhibitor-Pneumonitis beschrieben wurde.3 (Einzelheiten zu den in diesem Bericht erwähnten Gesundheitsbeurteilungen, Lungenfunktionsmessungen, bildgebenden Verfahren und zytometrischen Analysen vor der Behandlung und während der Nachbeobachtung finden sich in den Abbildungen S1 bis S5 im ergänzenden Anhang).

Die Behandlung mit einer inhalativen Formulierung von synthetischem vasoaktivem intestinalem Peptid (Aviptadil, Bachem) wurde in einer Dosis von 70 μg dreimal täglich als alternative Behandlung eingeleitet, um glukokortikoidbedingte Nebenwirkungen und systemische Immunsuppression zu vermeiden. Vasoaktives intestinales Peptid dämpft nachweislich Typ-1-Helfer-T-Zell-Reaktionen (Th1), indem es Effektor-T-Zellen hemmt und regulatorische T-Zellen über seine G-Protein-gekoppelten Rezeptoren (VPAC1 und VPAC2) fördert. Seine inhalative Anwendung bei Sarkoidose erhöht die alveolären regulatorischen T-Zellen und reduziert proinflammatorische Zytokine, was zu einer klinischen Verbesserung führt.4

Die Behandlung mit inhalativem vasoaktivem intestinalem Peptid führte zu einer klinischen und radiologischen Verbesserung der Lunge (Abbildung 1B). Die Analyse der BAL-Flüssigkeit zeigte eine verringerte alveoläre Lymphozytose mit reduzierter CD28-Expression und vermehrten regulatorischen T-Zellen. Die spontane und Lipopolysaccharid-induzierte Freisetzung von Tumornekrosefaktor, die das entzündliche Alveolarmilieu widerspiegelt, wurde während der Behandlung gedämpft. Vasoaktives intestinales Peptid wurde nicht mit toxischen Wirkungen in Verbindung gebracht und hatte keinen Einfluss auf Lymphozyten-Subtypen im peripheren Blut (Tabelle S1). Acht Wochen nach Beendigung der Behandlung kam es bei dem Patienten zu einer systemischen, nicht pulmonalen Progression der Melanomerkrankung.

Unsere Ergebnisse unterstützen inhalierte vasoaktive intestinale Peptide als lokale Therapie zur Verringerung der alveolären Entzündung bei Patienten mit Immun-Checkpoint-Inhibitor-Pneumonitis. Ob diese Therapie einen Einfluss auf die Tumorprogression hat, lässt sich anhand dieses Falles nicht feststellen. Es sind jedoch weitere Studien angezeigt, um zu untersuchen, ob vasoaktives intestinales Peptid eine therapeutische Option für die Immun-Checkpoint-Inhibitor-Pneumonitis sein kann.

Originallink: https://www.nejm.org/doi/full/10.1056/NEJMc2000343



Ein Plan bringt Stabilität. Auf festem Boden lässt sich Erfolg aufbauen.
Es gibt nichts Gutes oder Schlechtes, nur das Denken macht es so.
Immer besser werden wollen- in allem, was wir tun.

Top

28.12.2021 10:13
#16086
Babette
Bild des Benutzers Babette
Offline
Zuletzt online: 28.12.2021
Mitglied seit: 11.08.2010
Kommentare: 546
Kommentare
schönes Volumen heute bei anziehenden Kursen...

...könnte ein 30%-Move geben.

b.
Top

Seiten

   « first
   ‹ previous … 529 530 531 532 533 534 535 536 537

Drucken

   Seite drucken
   Bleiben Sie informiert
   YouTube
   Facebook
   Twitter
   Linked in
   Xing

© 1998-2021 / cash  |  Impressum  |  AGB
Alle Inhalte auf einen Klick

   Informieren
   Investieren
   Diskutieren
   Über uns
   Werbung

   News
       Top News
       Börsen Ticker
       Termine
       Alle News
       Newsletter
       Insider
       Insider Briefing
       Kolumne
       Invest - Stimmen zum Markt
       Alle Videos
   Börse und Märkte
       Kurse
       Aktien
       Devisen & Zinsen
       Rohstoffe & Edelmetalle
       Derivate
       Fonds & ETF
       Obligationen
   Ratgeber
       Themendossiers
       Rechner
       Börsenlexikon
   Services
       Börsenabos
       Basic-Abo
       Anleger-Abo
       Profi-Abo
       Realtime Kurse
       Newsletter
       Mobile
       cash als RSS Feed
       Über uns

 

https://youtu.be/l-MJj4J2BYc  :-)  

https://youtu.be/Pa9hBwvUIcs  

https://www.nrxpharma.com/...therapy-designation-request-for-zyesami/  

 
Ad hoc announcement pursuant to Art. 53 LR  
1


Relief Reports that its U.S. Collaboration Partner has Announced it has Filed a
Breakthrough Therapy Designation Request for Aviptadil in Patients at
Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir
and Other Approved Therapies
Geneva, Switzerland,  December  30, 2021 – RELIEF THERAPEUTICS Holding  SA (SIX: RLF, OTCQB: RLFTF,
RLFTY)  (“Relief”),  a  biopharmaceutical  company  seeking  to  provide  patients  therapeutic  relief  from
serious  diseases  with  high  unmet  need,  reported  today  that  the  parent  company  of  its  collaboration
partner,  NRx  Pharmaceuticals,  Inc.  (Nasdaq: NRXP) (“NRx”),  has  announced  it  has  filed  for  a  new
Breakthrough Therapy Designation (“BTD”) request with the U.S. Food and Drug Administration (“FDA”)
focused  on  patients  with  Critical  COVID-19  and  respiratory  failure  who  are  at  immediate  risk  of  death
despite treatment with Remdesivir and other approved therapies. According to the press release, the BTD
request  is  based  on  an  FDA  request  for  clinical  data  on  the  effectiveness  of  aviptadil  compared  to
Remdesivir and other approved therapies. The press release also reported patients treated with aviptadil
vs. placebo demonstrated a statistically significant (P=.03) 2.8-fold increased odds of being alive and free
of respiratory failure at  day 28 and day 60 and a highly  significant  (P=.006)  four-fold increased odds of
survival is seen in these patients. The  related NRx  press  release can be  accessed through the following
link.

ABOUT RELIEF
Relief  focuses  primarily  on  clinical-stage  programs  based  on molecules with  a  history  of  clinical  testing
and  use  in  human  patients  or  a  strong  scientific rationale. Relief’s lead drug candidate, RLF-100™
(aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S.
for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy,
in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the
worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate
release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle
Disorders  and  Maple  Syrup  Urine  Disease.  In  addition,  Relief's  recently  completed  acquisitions  of  APR
Applied Pharma Research SA and AdVita Lifescience GmbH, bring to Relief a diverse pipeline of marketed
and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in
the U.S. on OTCQB under the symbols RLFTF and RLFTY.  For more information, visit
www.relieftherapeutics.com.  Follow us on LinkedIn.
 
Ad hoc announcement pursuant to Art. 53 LR  
2




CONTACT:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Financial Officer and Treasurer  
contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES:  
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com


Disclaimer:  This  communication  expressly  or  implicitly  contains  certain  forward-looking  statements
concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks,
uncertainties and other factors, including (i) whether aviptadil will ever be approved in the U.S., the U.K.,
or the E.U. for the treatment of respiratory failure in patients with COVID-19, and (ii) those risks discussed
in RELIEF THERAPEUTICS Holding SA's press releases and filings with the SIX, which could cause the actual
results,  financial  condition,  performance  or  achievements  of  RELIEF  THERAPEUTICS  Holding  SA  to  be
materially different from any future results, performance or achievements expressed or implied by such
forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this
date and does not undertake to update any forward-looking statements contained herein as a result of
new information, future events or otherwise.

 

https://www.biospace.com/article/covid-19-update/...eXmP1ER_lQwPPn3-I  

https://www.relieftherapeutics.com/newsblog/...herapeutics-holding-sa

mal wieder nur, um die vergütungen für den vr von 1.5 mio auf 2.5 mio anzuheben???  

https://www.finanzen.ch/nachrichten/aktien/...el-aviptadil-1031074168  

https://relieftherapeutics.com/newsblog/...dil-suitable-for-human-use  

PRESS RELEASE  
1

Relief Therapeutics to Participate in Virtual Investor Conferences in January

Geneva, Switzerland, January 5, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY)
(“Relief”),  a  biopharmaceutical  company  seeking  to  provide  patients  therapeutic  relief  from  serious
diseases with high unmet need, today announced participation in the following virtual investor
conferences in January.  
• January  10-13:  H.C.  Wainwright  BioConnect  Virtual  Conference.  Jack  Weinstein,  Chief  Financial
Officer and Treasurer of Relief, will present a company overview at the conference. The on-demand
presentation will be available for viewing beginning January 10, at 7:00 am ET. An audio webcast of
the presentation will be available on the Relief website at: https://www.relieftherapeutics.com/news-
and-events and will be archived for a period of 90 days after the conference.
• January 10-13, 17-19: Biotech Showcase 2022. Mr. Weinstein will present a  corporate overview of
Relief which can be viewed on demand throughout the conference. Interested parties can register to
watch the presentation at https://bit.ly/RegisterBTS.  

ABOUT RELIEF
Relief  focuses  primarily  on  clinical-stage  programs  based  on molecules with  a  history  of  clinical  testing
and use in human patients or a strong scientific rationale. Relief’s drug candidate, RLF-100™ (aviptadil), a
synthetic  form  of  Vasoactive  Intestinal  Peptide  (VIP),  is  in  late-stage  clinical  testing  in  the  U.S.  for  the
treatment  of  respiratory  deficiency  due  to  COVID-19.  As  part  of  its  pipeline  diversification  strategy,  in
March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the
worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate
release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle
Disorders  and  Maple  Syrup  Urine  Disease.  In  addition,  Relief's  recently  completed  acquisitions  of  APR
Applied Pharma Research SA and AdVita Lifescience GmbH bring to Relief a diverse pipeline of marketed
and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in
the U.S. on OTCQB under the symbols RLFTF and RLFTY.  For more information, visit
www.relieftherapeutics.com.  Follow us on LinkedIn.


PRESS RELEASE  
2


CONTACT:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Financial Officer and Treasurer  
contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES:  
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com


Disclaimer:  This  communication  expressly  or  implicitly  contains  certain  forward-looking  statements
concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks,
uncertainties and other factors, including those risks discussed in RELIEF THERAPEUTICS Holding SA's press
releases and filings with the SIX, which could cause the actual results, financial condition, performance or
achievements  of  RELIEF  THERAPEUTICS  Holding  SA  to  be  materially  different  from  any  future  results,
performance or achievements expressed or implied by such forward-looking statements. RELIEF
THERAPEUTICS  Holding  SA  is  providing  this  communication  as  of  this  date  and  does  not  undertake  to
update any forward-looking statements contained herein as a result of new information, future events or
otherwise.
 

Moin Moin und erstmal allen ein gesundes und Erfolgreiches neues Jahr,
Was heißt das jetzt für uns die letzten Tage geht ja hier wieder mal bissl die Post ab.

Viele Grüße  

Warum wird die Schweizer Börse eigentlich nicht mehr angezeigt  

Lerner die Schweizer Eidgenossen machen um 17:30 Uhr die Börse dicht !! :-)

https://iapps.courts.state.ny.us/webcivil/...dcupDuGl10F0rgU01w%3D%3D  

Erstmal vielen dank

Aber Sixt wurde heute denn ganzen bei zumindest nicht angezeigt  

am besten gehst du über cash.ch rein da hast du dann alles !
Noch eine schöne dunkelgrüne Woche euch allen !! :-)  

Ad hoc announcement pursuant to Art. 53 LR  
1


Relief Reports that its U.S. Collaboration Partner has announced that it has
Submitted an Application to the FDA seeking Emergency Use Authorization for
Aviptadil to Treat Patients at Immediate Risk of Death from COVID-19 Despite
Treatment with Remdesivir and Other Approved Therapies
Geneva, Switzerland, January 6, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY)
(“Relief”),  a  biopharmaceutical  company  seeking  to  provide  patients  therapeutic  relief  from  serious
diseases  with  high  unmet  need,  reported  today  that  the  parent  company,  NRx  Pharmaceuticals,  Inc.
(Nasdaq: NRXP) (“NRx”), of its collaboration partner with respect to aviptadil, NeuroRx, Inc. ("NeuroRx")  
has  announced  that  it  has  submitted  an  application  to  the  FDA  seeking  emergency  use  authorization
("EUA") for the use of aviptadil to treat patients with critical COVID-19 who are at immediate risk of death
from  respiratory  failure  despite  treatment  with  approved  therapy  including  Remdesivir  and  who  are
ineligible  for  enrollment  into  the  ACTIV-3b  NIH-sponsored  trial.  The  related  NRx  press  release  can  be
accessed through the following link.

Relief also updated the market on recent activities in its pending lawsuit against NeuroRx and NeuroRx's
CEO, Jonathan Javitt (collectively, the "Defendants"), relating to the parties' collaboration agreement with
respect to the development and commercialization of aviptadil. Relief reported that the Defendants have
filed two motions with the Court: (i) a motion to dismiss seeking the dismissal of Jonathan Javitt from the
case for lack of personal jurisdiction, or, in the alternative, on the merits, and (ii) a motion to strike certain
statements  made  in  Relief's  complaint.  Relief  has  begun  its  review  of  the  defendants'  filings  and  will
respond at a future time in an appropriate filing with the Court. While there can be no assurance, Relief
remains confident in the statements made in its complaint and in the validity of its claims against NeuroRx
and  Jonathan  Javitt.  Relief  also  reported  that  its  previously  announced mediation  with  the Defendants
seeking to amicably resolve the litigation is currently scheduled for late February 2022.

ABOUT RELIEF
Relief  focuses  primarily  on  clinical-stage  programs  based  on  molecules with  a  history  of  clinical  testing
and use in human patients or a strong scientific rationale. Relief’s lead drug candidate, RLF-100™
(aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S.
for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy,
in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the
worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate
release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle
Disorders and Maple Syrup Urine Disease. In addition, Relief's recently completed acquisitions of APR  

Ad hoc announcement pursuant to Art. 53 LR  
2


Applied Pharma Research SA and AdVita Lifescience GmbH, bring to Relief a diverse pipeline of marketed
and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in
the U.S. on OTCQB under the symbols RLFTF and RLFTY.  For more information, visit
www.relieftherapeutics.com.  

Follow us on LinkedIn.


CONTACT:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Financial Officer and Treasurer  
contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES:  
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com


Disclaimer:  This  communication  expressly  or  implicitly  contains  certain  forward-looking  statements
concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks,
uncertainties and other factors, including (i) whether NeuroRx's recently submitted application to the FDA
seeking for EUA for aviptadil to treat patients with critical COVID-19 who are at immediate risk of death
from  respiratory  failure  despite  treatment  with  approved  therapy  including  Remdesivir  and  who  are
ineligible  for  enrollment  into  the  ACTIV-3b  NIH-sponsored  trial  will  be  approved,  (ii)  whether  RELIEF
THERAPEUTICS  Holding  SA  will  be  successful  in  its  lawsuit  against  NRx's  subsidiary,  NeuroRx,  and
NeuroRx's CEO, Jonathan Javitt, (iii) whether the mediation will be successful, (iv) whether aviptadil will
ever be approved in the U.S., the U.K., or the E.U. for the treatment of respiratory failure in patients with
COVID-19 or any other disease, and (v) those risks discussed in RELIEF THERAPEUTICS Holding SA's press
releases and filings with the SIX, which could cause the actual results, financial condition, performance or
achievements  of  RELIEF  THERAPEUTICS  Holding  SA  to  be  materially  different  from  any  future  results,
performance or achievements expressed or implied by such forward-looking statements. RELIEF
THERAPEUTICS  Holding  SA  is  providing  this  communication  as  of  this  date  and  does  not  undertake  to
update any forward-looking statements contained herein as a result of new information, future events or
otherwise.

 

https://miamicourant.com/stories/...-be-used-for-emergencies-like-now  

Ende Jahr 15 Fr?
Ineos bekommt wohl doch noch seine Rendite.
 

und habe bei 0,055 Franken noch mal gering aufgestockt . Bin zufrieden
mit einem Franken in 2024 wenn es in Rente geht als zusätzliche Alters-
vorsorge . Geht mehr freuen sich die Kinder und Enkel !! Dir und allen
Anderen wünsche ich natürlich nen riesigen Schluck aus der Pulle ! Das
Jahr 2022 bleibt spannend und Relief ist und bleibt ein Krimi erster Sahne !! :-)  

https://www.ihwjournal.com/en_gb/tag/sarcov2/  

https://journals.lww.com/ccejournal/Fulltext/2022/...ery_From.1.aspx#